Galantamine

butyrylcholinesterase ; Homo sapiens







155 Article(s)
Download
PMID
Title
Pub. Year
#Total Relationships
51 21817177 [Newly approved drugs for Alzheimer disease: effectiveness and limitation]. 2011 Aug 1
52 21872646 Synergistic inhibition of butyrylcholinesterase by galantamine and citalopram. 2011 Dec 4
53 22397284 Alzheimer's dementia: current data review. 2011 Dec 1
54 20113148 Galantamine for Alzheimer's disease. 2010 Mar 3
55 20156462 Neurochemical basis for symptomatic treatment of Alzheimer's disease. 2010 Sep-Oct 2
56 20169037 Galantamine-ER for the treatment of mild-to-moderate Alzheimer's disease. 2010 Feb 2 2
57 20205672 Effects of cholinesterase inhibitors on the activities and protein levels of cholinesterases in the cerebrospinal fluid of patients with Alzheimer's disease: a review of recent clinical studies. 2010 Feb 3
58 20593742 [Oral galantamine versus rivastigmine transdermal patch: a descriptive study at a memory clinic in The Netherlands]. 2010 Jun 1
59 20658794 Discontinuation of cholinesterase inhibitor treatment and determinants thereof in the Netherlands: A retrospective cohort study. 2010 Aug 1 1
60 21199749 Alzheimer's disease: aging, insomnia and epigenetics. 2010 Dec 1
61 21335298 Evaluation of the effects of galantamine on cardiac function in elderly patients with Alzheimer's disease. 2010 Oct 1
62 21598738 [Cholinesterase inhibitors for treating dementia. Review]. 2010 1
63 18949462 Galantamine-induced improvements in cognitive function are not related to alterations in alpha(4)beta (2) nicotinic receptors in early Alzheimer's disease as measured in vivo by 2-[18F]fluoro-A-85380 PET. 2009 Jan 1
64 19182463 Pharmacological interventions in primary care: hopes and illusions. 2009 1
65 19374459 Novel regimens and delivery systems in the pharmacological treatment of Alzheimer's disease. 2009 1
66 19424085 Electroencephalographic effects of galantamine in major depressive disorder. 2009 Jun 1
67 19657549 Trospium and cognition in patients with late onset Alzheimer disease. 2009 Oct 1
68 18264153 [Cholinesterase inhibitors in the treatment of dementia--are they useful in clinical practice?]. 2008 Jan 31 1
69 18316756 Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. 2008 Mar 4 1
70 18686744 Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis. 2008 1
71 18991634 The therapeutical potential of alpha-synuclein antiaggregatory agents for dementia with Lewy bodies. 2008 1
72 17442521 Regional brain activity after prolonged cholinergic enhancement in early Alzheimer's disease. 2007 Jul 1
73 17466645 Effective pharmacologic management of Alzheimer's disease. 2007 May 1
74 17848422 Evaluation of centrally acting cholinesterase inhibitor exposures in adults. 2007 Oct 1
75 17908053 Pharmacogenetic aspects of therapy with cholinesterase inhibitors: the role of CYP2D6 in Alzheimer's disease pharmacogenetics. 2007 Sep 1
76 17926835 Cholinesterase inhibitors: tremor and exacerbation of Parkinson's disease. 2007 Oct 1
77 18020110 Pharmacotherapy of Alzheimer disease. 2007 Oct 1
78 16289855 Novel tricyclic quinazolinimines and related tetracyclic nitrogen bridgehead compounds as cholinesterase inhibitors with selectivity towards butyrylcholinesterase. 2006 Mar 15 2
79 16323253 A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease. 2006 Jan 1
80 16373816 Case of the month: rivastigmine (Exelon) toxicity with evidence of respiratory depression. 2006 Jan 1
81 16437436 Galantamine for Alzheimer's disease and mild cognitive impairment. 2006 Jan 25 1
82 16449754 Beneficial effect of cholinesterase inhibitor medications on recognition memory performance in mild to moderate Alzheimer's disease: preliminary findings. 2006 Mar 1
83 16533671 Changes in cerebral neurotransmitters and metabolites induced by acute donepezil and memantine administrations: a microdialysis study. 2006 Mar 31 1
84 16720956 Current and emerging pharmacological treatment options for dementia. 2006 1
85 16806095 Galantamine improves cognition in schizophrenic patients stabilized on risperidone. 2006 Sep 15 1
86 16938240 [Mortality-associated factors in patients with Alzheimer's disease treated with galantamine]. 2006 Jul 8 1
87 16989488 Cholinesterase inhibitors in the clinical management of Alzheimer's disease: importance of early and persistent treatment. 2006 Jul-Aug 1
88 17032609 [Medical treatment of Alzheimer's disease]. 2006 Oct 2 1
89 17033976 [Retrospective comparative analysis of antidementia medication persistence patterns in Spanish Alzheimer's disease patients treated with donepezil, rivastigmine, galantamine and memantine]. 2006 Oct 16-31 1
90 17060346 Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology. 2006 Nov 1
91 23862185 Galantamine for vascular cognitive impairment. 2006 Jan 25 1
92 15654502 Symptomatic effect of donepezil, rivastigmine, galantamine and memantine on cognitive deficits in the APP23 model. 2005 Jun 1
93 15785036 Cholinesterase inhibitor affects the amyloid precursor protein isoforms in patients with Alzheimer's disease. 2005 1
94 15863734 Cholinesterase inhibitors in the treatment of dementia. 2005 Mar 1
95 15883258 Metabolic patterns associated with the clinical response to galantamine therapy: a fludeoxyglucose f 18 positron emission tomographic study. 2005 May 1
96 16078659 [Pharmacological therapy in Alzheimer's disease. Current clinical practice in The Netherlands]. 2005 Jul 1
97 16197661 Early onset effects of galantamine treatment on attention in patients with Alzheimer's disease. 2005 Sep 1
98 16273995 Effects of galantamine on working memory and global functioning in patients with mild cognitive impairment: a double-blind placebo-controlled study. 2005 Sep-Oct 1
99 16336020 Modelling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer's disease. 2005 1
100 17203561 The expert consensus guideline series. Treatment of dementia and its behavioral disturbances. Introduction: methods, commentary, and summary. 2005 Jan 1